Synthetic drugs targeting the PI3K/AKT/mTOR pathway have essential roles in managing keloid formation by interfering with the intracellular signaling mechanisms that modulate cell growth, proliferation, and survival, all of which are hyperactive in keloid fibroblasts (Chen et al., 2022a). The gene discussed is MTOR; the disease is keloid.